Epidemiologic design and analysis for proteomic studies: A primer on -omic technologies

American Journal of Epidemiology

Volumn 181, Issue 9, 2015, Pages 635-647

  Mischak, Harald ^a   Critselis, Elena ^a   Hanash, Samir ^a   Gallagher, William M ^a   Vlahou, Antonia ^a   Ioannidis, John P A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; epidemiologic methods; proteomics; research design; statistics; translational medical research

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALBUMIN; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; CHROMOGRANIN A; CLUSTERIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRINOGEN; MEMBRANE ASSOCIATED PROGESTERONE RECEPTOR COMPONENT 1; NUCLEAR MATRIX PROTEIN 22; PREALBUMIN; PROTEIN; SPIRONOLACTONE; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG;

BIOMARKER; EPIDEMIOLOGY; GENETIC MARKER; MOLECULAR ANALYSIS; PROTEOMICS; PUBLIC HEALTH; RESEARCH WORK; TECHNOLOGICAL CHANGE;

ACUTE KIDNEY FAILURE; AGING; ALZHEIMER DISEASE; ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; CAPILLARY ELECTROPHORESIS; CHRONIC KIDNEY DISEASE; COLORECTAL CANCER; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; HUMAN; INTERDISCIPLINARY COMMUNICATION; KIDNEY POLYCYSTIC DISEASE; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONGITUDINAL STUDY; LUNG ADENOCARCINOMA; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PREDICTIVE VALUE; PREECLAMPSIA; PRIMARY SCLEROSING CHOLANGITIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; PUBLIC HEALTH; SYSTEMATIC REVIEW; TWO DIMENSIONAL ELECTROPHORESIS; EPIDEMIOLOGY;

EPIDEMIOLOGIC STUDIES; HUMANS; PROTEOMICS;

EID: 84928914465     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu462     Document Type: Article

References (110)

1. Decramer S, Gonzalez de Peredo A, Breuil B, et al. Urine in clinical proteomics. Mol Cell Proteomics. 2008;7(10): 1850-1862.
2. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2010;56(2):177-185.
3. Molina F, Dehmer M, Perco P, et al. Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant. 2010;25(4):1015-1018.
4. Mischak H, Allmaier G, Apweiler R, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010;2(46):46ps42.
5. Baker ES, Liu T, Petyuk VA, et al. Mass spectrometry for translational proteomics: progress and clinical implications. Genome Med. 2012;4(8):63.
6. Lescuyer P, Hochstrasser D, Rabilloud T. How shall we use the proteomics toolbox for biomarker discovery? J Proteome Res. 2007;6(9):3371-3376.
7. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1(11):845-867.
8. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly available database. Proteomics. 2005;5(13): 3226-3245.
9. Metzger J, Schanstra JP, Mischak H. Capillary electrophoresis-mass spectrometry in urinary proteome analysis: current applications and future developments. Anal Bioanal Chem. 2009;393(5):1431-1442.
10. Rodríguez-Suárez E, Siwy J, Zürbig P, et al. Urine as a source for clinical proteome analysis: from discovery to clinical application. Biochim Biophys Acta. 2014;1844(5): 884-898.
11. Skold K, Alm H, Scholz B. The impact of biosampling procedures on molecular data interpretation. Mol Cell Proteomics. 2013;12(6):1489-1501.
12. Kolch W, Neusüss C, Pelzing M, et al. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev. 2005;24(6):959-977.
13. Bowen RA, Hortin GL, Csako G, et al. Impact of blood collection devices on clinical chemistry assays. Clin Biochem. 2010;43(1-2):4-25.
14. Mischak H, Kolch W, Aivaliotis M, et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl. 2010; 4(4):464-478.
15. Mertins P, Yang F, Liu T, et al. Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014;13(7):1690-1704.
16. Alkhalaf A, Zürbig P, Bakker SJ, et al. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One. 2010;5(10): e13421.
17. Wiesner C, Hannum C, Reckamp K, et al. Consistency of a two clinical site sample collection: a proteomics study. Proteomics Clin Appl. 2010;4(8-9):726-738.
18. Siwy J, Schanstra JP, Argiles A, et al. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol Dial Transplant. 2014;29(8):1563-1570.
19. Dakna M, He Z, Yu WC, et al. Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(13):1250-1258.
20. Fliser D, Novak J, Thongboonkerd V, et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol. 2007;18(4):1057-1071.
21. Maryáš J, Faktor J, Dvořáková M, et al. Proteomics in investigation of cancer metastasis: functional and clinical consequences and methodological challenges. Proteomics. 2014;14(4-5):426-440.
22. Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond). 2005; 108(5):369-383.
23. Valledor L, Jorrín J. Back to the basics: maximizing the information obtained by quantitative two dimensional gel electrophoresis analyses by an appropriate experimental design and statistical analyses. J Proteomics. 2011;74(1): 1-18.
24. Wood SL, Westbrook JA, Brown JE. Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment. Cancer Treat Rev. 2014;40(1): 139-152.
25. Mischak H, Coon JJ, Novak J, et al. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev. 2009;28(5): 703-724.
26. Klein J, Papadopoulos T, Mischak H, et al. Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. Electrophoresis. 2014;35(7):1060-1064.
27. Mullen W, Albalat A, Gonzalez J, et al. Performance of different separation methods interfaced in the same MS-reflection TOF detector: a comparison of performance between CE versus HPLC for biomarker analysis. Electrophoresis. 2012;33(4):567-574.
28. Matzke MM, Brown JN, Gritsenko MA, et al. A comparative analysis of computational approaches to relative protein quantification using peptide peak intensities in label-free LC-MS proteomics experiments. Proteomics. 2013;13(3-4): 493-503.
29. Pan S, Aebersold R, Chen R, et al. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res. 2009;8(2):787-797.
30. Percy AJ, Parker CE, Borchers CH. Pre-Analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies. Bioanalysis. 2013;5(22): 2837-2856.
31. Chambers AG, Percy AJ, Simon R, et al. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev Proteomics. 2014; 11(2):137-148.
32. McDonnell LA, Corthals GL, Willems SM, et al. Peptide and protein imaging mass spectrometry in cancer research. J Proteomics. 2010;73(10):1921-1944.
33. Mischak H, Apweiler R, Banks RE, et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl. 2007;1(2):148-156.
34. Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One. 2010;5(12):e15004.
35. Neiman M, Hedberg JJ, Dönnes PR, et al. Plasma profiling reveals human fibulin-1 as candidate marker for renal impairment. J Proteome Res. 2011;10(11):4925-4934.
36. Babel I, Barderas R, Peláez-García A, et al. Antibodies on demand: a fast method for the production of human scFvs with minimal amounts of antigen. BMC Biotechnol. 2011;11:61.
37. Gerdes MJ, Sevinsky CJ, Sood A, et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A. 2013;110(29): 11982-11987.
38. Vitzthum F, Behrens F, Anderson NL, et al. Proteomics: from basic research to diagnostic application. A review of requirements &needs. J Proteome Res. 2005;4(4):1086-1097.
39. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359(9306):572-577.
40. Check E. Proteomics and cancer: running beforewe can walk? Nature. 2004;429(6991):496-497.
41. Dakna M, Harris K, Kalousis A, et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics. 2010;11:594.
42. Larrañaga P, Calvo B, Santana R, et al. Machine learning in bioinformatics. Brief Bioinform. 2006;7(1):86-112.
43. Sampson DL, Parker TJ, Upton Z, et al. A comparison of methods for classifying clinical samples based on proteomics data: a case study for statistical and machine learning approaches. PLoS One. 2011;6(9):e24973.
44. Carty DM, Siwy J, Brennand JE, et al. Urinary proteomics for prediction of preeclampsia. Hypertension. 2011;57(3): 561-569.
45. Delles C, Schiffer E, von Zur Muhlen C, et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens. 2010; 28(11):2316-2322.
46. Good DM, Zürbig P, Argilés A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics. 2010;9(11):2424-2437.
47. Jahn H, Wittke S, Zürbig P, et al. Peptide fingerprinting of Alzheimers disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One. 2011;6(10):e26540.
48. Kistler AD, Mischak H, Poster D, et al. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2009;76(1): 89-96.
49. Metzger J, Kirsch T, Schiffer E, et al. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int. 2010;78(12): 1252-1262.
50. Schiffer E, Vlahou A, Petrolekas A, et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res. 2009;15(15):4935-4943.
51. Zürbig P, Decramer S, Dakna M, et al. The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics. 2009;9(8):2108-2117.
52. Lankisch TO, Metzger J, Negm AA, et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology. 2011;53(3):875-884.
53. Zürbig P, Jerums G, Hovind P, et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes. 2012; 61(12):3304-3313.
54. Roscioni SS, de Zeeuw D, Hellemons ME, et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia. 2013;56(2):259-267.
55. Argilés A, Siwy J, Duranton F, et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One. 2013;8(5):e62837.
56. Mischak H, Vlahou A, Ioannidis JP. Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem. 2013;46(6):432-443.
57. Stalmach A, Albalat A, Mullen W, et al. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis. 2013;34(11): 1452-1464.
58. Cheng J, Xie HY, Xu X, et al. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 2011;310(1):35-45.
59. Liu YF, Xiao ZQ, Li MX, et al. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 2009;217(1):54-64.
60. MaY, Peng J, LiuW, et al. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteomics. 2009;8(8): 1878-1890.
61. Mölleken C, Sitek B, Henkel C, et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009;49(4):1257-1266.
62. ODwyer D, Ralton LD, OShea A, et al. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One. 2011;6(11):e27718.
63. Ottervald J, Franzén B, Nilsson K, et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J Proteomics. 2010;73(6):1117-1132.
64. Pang J, Liu WP, Liu XP, et al. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J Proteome Res. 2010;9(1): 216-226.
65. Perrin RJ, Craig-Schapiro R, Malone JP, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimers disease. PLoS One. 2011;6(1): e16032.
66. Verrills NM, Irwin JA, He XY, et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011; 183(12):1633-1643.
67. Zhang L, Xiao H, Karlan S, et al. Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One. 2010;5(12):e15573.
68. Kim HJ, Kang HJ, Lee H, et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res. 2009;8(3):1368-1379.
69. Bai DS, Dai Z, Zhou J, et al. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology. 2009;49(2):460-470.
70. Comabella M, Fernández M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010;133(4):1082-1093.
71. Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55(2):483-490.
72. Wang CL, Wang CI, Liao PC, et al. Discovery of retinoblastoma-Associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J Proteome Res. 2009;8(10): 4428-4440.
73. Xue H, Lü B, Zhang J, et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res. 2010;9(1):545-555.
74. Wingren C, Sandström A, Segersvärd R, et al. Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res. 2012;72(10):2481-2490.
75. Farlow EC, Patel K, Basu S, et al. Development of a multiplexed tumor-Associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010;16(13):3452-3462.
76. Dieplinger H, Ankerst DP, Burges A, et al. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(4): 1127-1133.
77. Moore LE, Pfeiffer RM, Zhang Z, et al. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer. 2012;118(1):91-100.
78. Zhu CS, Pinsky PF, Cramer DW, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011;4(3):375-383.
79. Chadeau-Hyam M, Campanella G, Jombart T, et al. Deciphering the complex: methodological overview of statistical models to derive OMICS-based biomarkers. Environ Mol Mutagen. 2013;54(7):542-557.
80. Bonassi S, Taioli E, Vermeulen R. Omics in population studies: a molecular epidemiology perspective. Environ Mol Mutagen. 2013;54(7):455-460.
81. Oberg AL, Vitek O. Statistical design of quantitative mass spectrometry-based proteomic experiments. J Proteome Res. 2009;8(5):2144-2156.
82. Wu SH, Black MA, North RA, et al. A statistical model to identify differentially expressed proteins in 2D PAGE gels. PLoS Comput Biol. 2009;5(9):e1000509.
83. Biron DG, Brun C, Lefevre T, et al. The pitfalls of proteomics experiments without the correct use of bioinformatics tools. Proteomics. 2006;6(20):5577-5596.
84. Urfer W, Grzegorczyk M, Jung K. Statistics for proteomics: a review of tools for analyzing experimental data. Proteomics. 2006;6(suppl 2):48-55.
85. Cairns DA. Statistical issues in quality control of proteomic analyses: good experimental design and planning. Proteomics. 2011;11(6):1037-1048.
86. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimers diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11): 1359-1362.
87. Levin Y. The role of statistical power analysis in quantitative proteomics. Proteomics. 2011;11(12):2565-2567.
88. Zhou C, Simpson KL, Lancashire LJ, et al. Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery. J Proteome Res. 2012; 11(4):2103-2113.
89. Ioannidis JP. A roadmap for successful applications of clinical proteomics. Proteomics Clin Appl. 2011;5(5-6):241-247.
90. Ransohoff DF. Challenges and opportunities in evaluating diagnostic tests. J Clin Epidemiol. 2002;55(12):1178-1182.
91. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem. 2010;56(2):327-329.
92. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst. 2005; 97(4):315-319.
93. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst. 2010;102(19): 1462-1467.
94. Füzéry AK, Levin J, Chan MM, et al. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics. 2013;10:13.
95. Gu YM, Thijs L, Liu YP, et al. The urinary proteome as correlate and predictor of renal function in a population study. Nephrol Dial Transplant. 2014;29(12):2260-2268.
96. Huber S, Schwentner C, Taeger D, et al. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int. 2012;110(5):699-708.
97. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol. 2007; 60(12):1205-1219.
98. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer. 2005;5(2): 142-149.
99. Mischak H, Ioannidis JP, Argiles A, et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest. 2012;42(9):1027-1036.
100. LaBaer J. Improving international research with clinical specimens: 5 achievable objectives. J Proteome Res. 2012; 11(12):5592-5601.
101. Siontis KC, Siontis GC, Contopoulos-Ioannidis DG, et al. Diagnostic tests often fail to lead to changes in patient outcomes. J Clin Epidemiol. 2014;67(6):612-621.
102. Schanstra JP, Zürbig P, Alkhalaf A, et al. Diagnosis and prediction of CKD progression by assessment of urinary peptides [published online ahead of print January 14, 2015]. J Am Soc Nephrol. (doi:10.1681/ASN.2014050423).
103. Horvath AR, Lord SJ, StJohn A, et al. From biomarkers to medical tests: the changing landscape of test evaluation. Clin Chim Acta. 2014;427:49-57.
104. Karanikolos M, Mladovsky P, Cylus J, et al. Financial crisis, austerity, and health in Europe. Lancet. 2013;381(9874): 1323-1331.
105. Ioannidis JP, Khoury MJ. Improving validation practices in omics research. Science. 2011;334(6060):1230-1232.
106. Schiffer E, Bick C, Grizelj B, et al. Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany. Int J Urol. 2012;19(2): 118-125.
107. Mischak H, Vlahou A, Righetti PG, et al. Putting value in biomarker research and reporting. J Proteomics. 2014;96: A1-A3.
108. Vlahou A. Back to the future in bladder cancer research. Expert Rev Proteomics. 2011;8(3):295-297.
109. Cho WC, Yip TT, Cheng WW, et al. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer. 2010;102(12):1731-1735.
110. Ng PC, Ang IL, Chiu RW, et al. Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants. J Clin Invest. 2010;120(8): 2989-3000.